Literature DB >> 2115551

An improved conjugation method for controlled covalent coupling of synthetic peptides to proteins using glutaraldehyde in a dialysis method.

N Zegers1, K Gerritse, C Deen, W Boersma, E Claassen.   

Abstract

Controlled and efficient conjugation of synthetic peptides to proteins, for use in immunization or in assay procedures, is a prerequisite for the immunological applications of synthetic peptides. This study describes a new method of conjugating synthetic peptides to proteins in such a way that no homopolymers of synthetic peptides or proteins occur. To achieve this, the protein is first activated with glutaraldehyde and subsequently excess glutaraldehyde is removed. Then coupling of the synthetic peptide to the activated protein occurs while subsequently the surplus reactive glutaraldehyde groups on the protein are blocked with lysine. Excess free peptide and lysine is then removed by dialysis. This improvement not only results in better defined conjugates when compared to classical glutaraldehyde coupling, but also in the consumption of smaller amounts of synthetic peptide during conjugate formation. When used for immunization we obtained similar and sometimes even better responses with the glutaraldehyde based conjugates than with succinimidyl (MBS) conjugates of the same peptides. The performance of the modified conjugates in ELISA procedures, immunization and immunocytochemistry suggests that they are superior to conjugates formed by classical glutaraldehyde coupling.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2115551     DOI: 10.1016/0022-1759(90)90048-z

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  10 in total

1.  Differences in the natural autoantibody patterns of patients with schizophrenia and normal individuals.

Authors:  P Lévy-Soussan; A Berneman; M F Poirier; A Galinowski; H Loo; J P Olié; S Avrameas
Journal:  J Psychiatry Neurosci       Date:  1996-03       Impact factor: 6.186

2.  A peptide derived from a polyreactive monoclonal anti-DNA natural antibody can modulate lupus development in (NZBxNZW)F1 mice.

Authors:  C Jouanne; S Avrameas; B Payelle-Brogard
Journal:  Immunology       Date:  1999-03       Impact factor: 7.397

3.  Type-specific immunodetection of human heart fatty acid-binding protein with polyclonal anti-peptide antibodies.

Authors:  A H Kleine; J F Glatz; F A van Nieuwenhoven; M I Vallinga; M H Salden; F T Bosman; W J Boersma; N D Zegers; G J van der Vusse
Journal:  Mol Cell Biochem       Date:  1990 Oct 15-Nov 8       Impact factor: 3.396

4.  Monoclonal antibodies to the circumsporozoite protein repeats of a Plasmodium vivax-like human malaria parasite and Plasmodium simiovale.

Authors:  V Udhayakumar; S H Qari; P Patterson; W E Collins; A A Lal
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

5.  A delayed-type hypersensitivity-inducing T-cell epitope of Semliki Forest virus mediates effective T-helper activity for antibody production.

Authors:  A Snijders; B J Benaissa-Trouw; H J Visser-Vernooy; I Fernandez; H Snippe; C A Kraaijeveld
Journal:  Immunology       Date:  1992-11       Impact factor: 7.397

6.  Generation of neutralizing antipeptide antibodies to the enzymatic domain of Pseudomonas aeruginosa exotoxin A.

Authors:  H S Elzaim; A K Chopra; J W Peterson; R Goodheart; J P Heggers
Journal:  Infect Immun       Date:  1998-05       Impact factor: 3.609

7.  A Combinatory Antibody-Antigen Microarray Assay for High-Content Screening of Single-Chain Fragment Variable Clones from Recombinant Libraries.

Authors:  Nina Persson; Bo Jansson; Nicolai Stuhr-Hansen; András Kovács; Charlotte Welinder; Lena Danielsson; Ola Blixt
Journal:  PLoS One       Date:  2016-12-21       Impact factor: 3.240

8.  Controlled Covalent Conjugation of a Tuberculosis Subunit Antigen (ID93) to Liposome Improved In Vitro Th1-Type Cytokine Recall Responses in Human Whole Blood.

Authors:  Babatunde Ayodeji Adeagbo; Akintunde Oluseto Akinlalu; Tony Phan; Jeff Guderian; Gerhardt Boukes; Elize Willenburg; Caryn Fenner; Oluseye Oladotun Bolaji; Christopher B Fox
Journal:  ACS Omega       Date:  2020-11-20

9.  Monoclonal antibodies reacting with the MUC2 mucin core protein.

Authors:  P L Devine; M A McGuckin; G W Birrell; R H Whitehead; G P Sachdev; P Shield; B G Ward
Journal:  Br J Cancer       Date:  1993-06       Impact factor: 7.640

10.  Induction of humoral immune responses and inhibition of metastasis in mice by a VEGF peptide-based vaccine.

Authors:  Faezeh Soltanpour Gharibdousti; Banafsheh Fazeli Delshad; Reza Falak; Nasrin Shayanfar; Mazdak Ganjalikhani Hakemi; Alireza Andalib; Gholam Ali Kardar
Journal:  Iran J Basic Med Sci       Date:  2020-04       Impact factor: 2.699

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.